Changxuan You

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen et al. · The Lancet Oncology · 2011 · 4K citations

Medicine, Pathology, Bronchial Neoplasm +8

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx

Jianpeng Chen, Yi Luan, Changxuan You et al. · Cell Calcium · 2010 · 134 citations

Tumor Biology, Ca2+ Influx, Molecular Physiology +10

CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients

Xiaotao Qian, Xuekun Song, Yuan He et al. · Biomedicine & Pharmacotherapy · 2015 · 126 citations

Poor Prognostic Biomarker, Biomarker (Medicine), Prognostic Biomarkers +10

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 119 citations · Full text

Medicine, Cancer Management, Phase Iii +6